-
1.发明公开POLYETHYLENE GLYCOL BASED PRODRUG OF ADRENOMEDULLIN AND USE THEREOF 有权ADRENOMEDULLIN-PRODRUG AUF POLYETHYLINGLYKOLBASIS UND VERWENDUNG DAVON
公开(公告)号：EP3075395A1
公开(公告)日：2016-10-05
申请号：EP15192265.5
申请日：2012-10-30
发明人： FLAMME, Ingo , KÖBBERLING, Johannes , LERCHEN, Hans-Georg , GRIEBENOW, Nils , SCHOHE-LOOP, Rudolf , WITTROCK, Sven , KÖLLNBERGER, Maria , WUNDER, Frank , REDLICH, Gordon , KNORR, Andreas , MARLEY, July , PRITCHARD, Iain
CPC分类号： C07K5/06017 , A61K9/007 , A61K38/22 , A61K45/06 , A61K47/60 , C07K5/02 , C07K5/06078 , C07K14/575
摘要： The invention relates medicaments comprising novel polyethylene glycol (PEG) based prodrugs of Adrenomedullin, or one of the salts thereof, solvates thereof or the solvates of salts thereof, in combination with an inert nontoxic pharmaceutically suitable excipient, wherein the medicament is in a pharmaceutical form for inhalation, its use for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, to specific PEG-adrenomedullin prodrugs and its synthesis intermediates.
摘要翻译： 本发明涉及包含新型聚乙二醇（PEG）基于前体药物的肾上腺髓质素或其盐之一，其溶剂合物或其盐的溶剂合物与惰性无毒药学上合适的赋形剂组合的药物，其中药物为药物形式 用于吸入，其用于治疗和/或预防特定PEG-肾上腺髓质素前体药物及其合成中间体的疾病，特别是心血管，水肿和/或炎症性疾病的疾病。
-
公开(公告)号：EP3075395B1
公开(公告)日：2017-11-22
申请号：EP15192265.5
申请日：2012-10-30
发明人： FLAMME, Ingo , KÖBBERLING, Johannes , LERCHEN, Hans-Georg , GRIEBENOW, Nils , SCHOHE-LOOP, Rudolf , WITTROCK, Sven , KÖLLNBERGER, Maria , WUNDER, Frank , REDLICH, Gorden , KNORR, Andreas , MARLEY, July , PRITCHARD, Iain
CPC分类号： C07K5/06017 , A61K9/007 , A61K38/22 , A61K45/06 , A61K47/60 , C07K5/02 , C07K5/06078 , C07K14/575
摘要： The invention relates medicaments comprising novel polyethylene glycol (PEG) based prodrugs of Adrenomedullin, or one of the salts thereof, solvates thereof or the solvates of salts thereof, in combination with an inert nontoxic pharmaceutically suitable excipient, wherein the medicament is in a pharmaceutical form for inhalation, its use for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, to specific PEG-adrenomedullin prodrugs and its synthesis intermediates.
-
3.发明授权POLYETHYLENE GLYCOL BASED PRODRUG OF ADRENOMEDULLIN AND USE THEREOF 有权西班牙语VERWENDUNG的ADRENOMEDULLIN-PRODRUG AUF POLYETHYLINGLYKOLBASIS
公开(公告)号：EP2773376B1
公开(公告)日：2016-01-13
申请号：EP12783566.8
申请日：2012-10-30
发明人： FLAMME, Ingo , KÖBBERLING, Johannes , LERCHEN, Hans-Georg , GRIEBENOW, Nils , SCHOHE-LOOP, Rudolf , WITTROCK, Sven , KÖLLNBERGER, Maria , WUNDER, Frank , REDLICH, Gorden , KNORR, Andreas , MARLEY, July , PRITCHARD, Iain
CPC分类号： C07K5/06017 , A61K9/007 , A61K38/22 , A61K45/06 , A61K47/60 , C07K5/02 , C07K5/06078 , C07K14/575
摘要： The invention relates medicaments comprising novel polyethylene glycol (PEG) based prodrugs of Adrenomedullin, or one of the salts thereof, solvates thereof or the solvates of salts thereof, in combination with an inert nontoxic pharmaceutically suitable excipient, wherein the medicament is in a pharmaceutical form for inhalation, its use for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, to specific PEG-adrenomedullin prodrugs and its synthesis intermediates.
摘要翻译： 本发明涉及包含新型聚乙二醇（PEG）基于前体药物的肾上腺髓质素或其盐之一，其溶剂化物或其盐的溶剂合物与惰性无毒药学上合适的赋形剂组合的药物，其中药物为药物形式 用于吸入，其用于治疗和/或预防特定PEG-肾上腺髓质素前体药物及其合成中间体的疾病，特别是心血管，水肿和/或炎症性疾病的疾病。
-
公开(公告)号：EP2773376A1
公开(公告)日：2014-09-10
申请号：EP12783566.8
申请日：2012-10-30
发明人： FLAMME, Ingo , KÖBBERLING, Johannes , LERCHEN, Hans-Georg , GRIEBENOW, Nils , SCHOHE-LOOP, Rudolf , WITTROCK, Sven , KÖLLNBERGER, Maria , WUNDER, Frank , REDLICH, Gorden , KNORR, Andreas , MARLEY, July , PRITCHARD, Iain
CPC分类号： C07K5/06017 , A61K9/007 , A61K38/22 , A61K45/06 , A61K47/60 , C07K5/02 , C07K5/06078 , C07K14/575
摘要： The invention relates medicaments comprising novel polyethylene glycol (PEG) based prodrugs of Adrenomedullin, or one of the salts thereof, solvates thereof or the solvates of salts thereof, in combination with an inert nontoxic pharmaceutically suitable excipient, wherein the medicament is in a pharmaceutical form for inhalation, its use for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, to specific PEG-adrenomedullin prodrugs and its synthesis intermediates.
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
